Table 2.
Anthropometric, lung function, phenotype, and treatment data according to the presence or absence of pneumonia.
| Variable | Pneumonia | No Pneumonia | p-Value |
|---|---|---|---|
| Male, n (%) | 69 (89.6) | 174 (88.8) | 0.843 |
| Age, years (SD) | 71.65 (8.90) | 66.55 (10.91) | 0.000 *** |
| Weight, kg (SD) | 75.06 (15.20) | 75.02 (17.52) | 0.984 |
| Height, m (SD) | 1.62 (0.08) | 1.63 (0.80) | 0.140 |
| BMI, kg/m2 (DE) | 28.53 (5.35) | 27.87 (5.55) | 0.369 |
| Active smoking, n (%) | 21 (27.3) | 71 (36.2) | 0.200 |
| Pulmonary function, % (SD) | |||
| FEV1 | 47.37 (13.20) | 49.14 (12.34) | 0.297 |
| FVC | 70.81 (14.82) | 74.11 (15.01) | 0.102 |
| Phenotypes, n (%) | |||
| Positive bronchodilator response | 15 (19.5) | 56 (28.6) | 0.016 * |
| Nonexacerbator | 38 (49.4) | 97 (49.5) | |
| Exacerbator with emphysema | 5 (6.5) | 22 (11.2) | |
| Exacerbator with chronic bronchitis | 19 (24.7) | 21 (10.7) | |
| Pharmacological treatment, n (%) | |||
| LAMA | 75 (97.4) | 179 (91.3) | 0.076 |
| LABA | 71 (92.2) | 171 (87.2) | 0.245 |
| ICS | 66 (85.7) | 146 (74.5) | 0.045 * |
| Respiratory therapies, n (%) | |||
| LTOT | 34 (44.2) | 57 (29.1) | 0.017 * |
| CPAP | 5 (6.5) | 26 (13.3) | 0.139 |
| BiPAP | 6 (7.8) | 8 (4.1) | 0.229 |
| Pneumococcal vaccination, n (%) | 21 (27.3) | 139 (70.9) | 0.000 *** |
* p < 0.05; *** p < 0.001.